Overview
As of the Year 2022, Therapeutic antibodies [multi-faceted proteins] have become the predominant class of new drugs positively impacting patients across the globe for treating several human diseases including cancer, autoimmune, and infectious diseases. This has influenced post Pandemic Research in Biopharma Companies for antibody therapy development from bench to bedside. Due to their high degree of specificity and generally favourable safety profiles, monoclonal antibodies have also emerged as one of the most promising and fastest growing classes of bio therapeutics. There are currently over 70 FDA-approved monoclonal antibodies and several hundred more in clinical development. We will highlight cutting edge technological and clinical advancements of interest also to a broad spectrum of Industry professionals, scientists & researchers here.
Major automation & digitalization technological advances over the past years –have facilitated the discovery and development of monoclonal antibody therapies & novel strategies are continually emerging to enhance their clinical potential.. Target validation, MOA, protein design, development time, and managing increasing costs of antibody manufacturing still remain as major challenges.
Cell therapy and gene therapy are overlapping fields of biomedical research and treatment. Both therapies work differently, however aim to treat, prevent, or potentially cure diseases and both approaches have the potential to alleviate the underlying cause of genetic diseases and acquired diseases . Professionals will elaborate on this crucial aspect.
Who should attend
CEOs – Biopharmaceuticals, Biotechnology, Vaccines
CTOs Digital vendors
Research & Development scientists – Biopharmaceuticals, Biotechnology, Vaccines
IT Cell
HODs of different Cross functions – Biopharmaceuticals, Biotechnology, Vaccines
VPs, Senior Managers, Project Managers
Research & Development
Project Management
QA/QC
Regulatory
IT
Why attend?
Knowledge enhancement via presentation & Panel discussions by Industry experts
Valuable take-aways by interacting with Resource persons from Industry & Evolving Technology developers & providers
Understanding challenges thrown by New Advents & Innovations during Panel discussion & Fireside chat session to carve out the best way forward for Monoclonal antibodies development & optimum utilization of Cell therapy & Gene therapy
Assimilating new opportunities , risks associated, challenges & implications thereof to translate/implement learning & enrichment on shop floor at respective work zones for churning out cost effective therapies for global patients with respect to difficult to treat or non-treatable diseases
Speakers
Dr. Niti M. Jetly
Application Specialist, Molecular Devices
Dr. Satya Lakshmi Oruganty
Lead – Business Consulting, IDBS
Dr. Satya Lakshmi holds a PhD in molecular biology from CCMB and has worked across the drug discovery and development organisations in India for over a decade now. She brings expertise of research lab workflows and knowledge of informatics and IT solutions to provide digital transformation consultancy to R&D labs. She also holds a certificate in business excellence from
Columbia University, New York and is known to collaborate with customers across the globe in building informatics solutions for improved research outcomes.
Dr. Shubhadeep Sinha
Senior Vice-President and Medical Director Hetero Group of Companies
Dr. Kishore J. R. Kunapuli
Consultant for the development of CAR-NK Cell Therapy Products, Pulse Pharmaceuticals
Mukund Joshi
Field Marketing, Beckman Coulter Life Sciences
Mukund Joshi leads Field marketing for Beckman coulter life sciences in India and neighbouring markets. He began his professional career at Biocon Biopharmaceuticals in a laboratory. He has held roles of increasing responsibility; from technical to commercial management in the past 14 years.
He is a postgraduate in Biotechnology from Bangalore university and has as executive management certification from IIM-B.
Dr. Tarun Sharma
Director, Sai Life Science
Praveen Kumar Baheti
Associate Vice President (IT Infrastructure & Modernization), Biological E. Limited
Rajan Sankaran
General Manager, Cytiva India
Yang Shi
PhD, MBA , Vice President, Global Sales at Phenomenex, a Danaher Company
Chitti Babbu
Group CIO, Autobindo Pharma
Dr. Lingala Rajendra
Vice President & Head - R & D
Over 30 years of research experience in Vaccine development programs, Technical due diligence, Pilot facility design & execution, Process development, Process validation, Formulation development for thermostable vaccines, Clinical batches manufacturing, cGMP fill finish, Clinical trials, Regulatory filing and approvals. Successfully transferred the manufacturing process for various vaccine candidates from R & D scale to commercial scale.
Served in different capacities at Indian Immunologicals Limited overseeing the process development for various Bacterial & Viral vaccines (Recombinant & Conventional), Conjugate vaccines, Monoclonal antibodies & Bio-therapeutics. Fields of expertise include Process Development, Formulation Development – Thermostable vaccines, vaccine delivery devices and combination vaccines for Pediatric use.
Prior to joining Indian Immunologicals Limited served as Sr. General Manager, Bio Process Head at Shantha Biotechniques Limited (A Sanofi Company) and as Senior Director at MSD Wellcome Trust Hilleman Labs overseeing analytical and formulation development.
Dr. Likhesh Sharma
Product Manager Cell & Gene Therapy, Cytiva
Dr.Likhesh Sharma leads the Cytiva’s Cell Therapy business as product manager in South Asia. He has more than 15 years of experience in the field of biotechnology; his expertise ranges from protein engineering and characterisation to cell analysis and cell therapy. He earned his PhD in Biophysics from Indian Institute of Science, Bangalore, and undergraduate honours degree from Delhi University.
Agenda
6:00 PM : Welcome Address
Welcome Address – Ashish Chauhan, Director, BlueTech Media
6:05 PM: Key Note Address
Key Note Address: Mr. Rajan Sankaran, General Manager, Cytiva India
6:15 PM: Panel Discussion
Panel Discussion:
Monoclonal antibodies (MABs) & Cell Therapy & Gene Therapy: A major driver of overall biopharmaceutical product sales, to cure a wide array of untreatable and difficult-to-treat diseases.
- Emergence & a major class of therapeutic agents [to limit or modify SARS-CoV-2 infection] – a major advance in the control of the COVID-19 pandemic.
- Recent Advances & Cutting edge findings from B cells to antibody design and implications for vaccines.
- Cell Therapy & Gene therapy – safe & affordable global cures via Cell Therapy & Gene therapy – Overview of gene therapies up for FDA approval over the next five years- to alleviate the underlying cause of genetic diseases and acquired diseases
- Returns of Investments on development & marketing of Cell & Gene Therapy Efforts by Biopharma companies
Moderator – Mukund Joshi, Field Marketing, Beckman Coulter Life Sciences
Panelists –
-
- Dr. Shubhadeep Sinha, Senior Vice- President & Medical Director, Hetero Group Of Companies
- Dr. Kishore J. R. Kunapali, Chief Scientific Officer – Cell Therapeutics, Pulse Pharmaceuticals
- Dr. Tarun Sharma, Director, Sai Life Sciences Ltd.
- Dr. Likhesh Sharma, Product Manager Cell & Gene Therapy, Cytiva
7:00 PM: Presentation
Presentation: Role of automation and digitalization post pandemic
- AI Robotic processes
- Digital tools and Platforms
Speaker : Dr. Niti M. Jetly, Application Specialist, Molecular Devices
7:20 PM: Fireside Chat
Fireside Chat: Advantages of increasing levels of automation and digitalization incorporated into industrial workflows in biopharmaceutical sector
- Purpose – to monitor for contamination events and inform development of standard operating procedures to minimize the risk of contamination.
- Result– process improvement, greater process control, improved traceability, and cost reduction – coming from reduced manual steps and from optimizing personnel, equipment, and material workflows.
Moderator: Dr. Satya Lakshmi Oruganty, Lead – Business Consulting, IDBS
Panelists:
- Mr. Chitti Babbu, Group CIO, Autobindo Pharma
- Dr. Lingala Rajendra, Vice President & Head – R & D
- Mr. Praveen Kumar Baheti, Associate Vice President (IT Infrastructure & Modernization), Biological E. Limited
7:50 PM: Closing Remarks
Closing Remarks: Mr. Yang Shi, PhD, MBA , Vice President, Global Sales at Phenomenex, a Danaher Company
Register Now
7718843607
marketing@bluetech-media.com
Terms & Conditions
Beckman | Cytiva | Molecular Devices | IDBS | Pall | Sciex | Phenomenex